Evidence map›Paper›PMID 37291924›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2023

[Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study].

M L Zhang, Q P Liu, C Gong, J M Wang, T J Zhou, X F Liu, P Shen, H B Lin, X Tang, P Gao

Open access · greenAbstract readEnglish Abstract
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

M L ZhangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Q P LiuDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
C GongDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
J M WangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
T J ZhouDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
X F LiuDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
P ShenYinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China.
H B LinYinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China.
X TangDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
P GaoDepartment of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China.
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the expected population impact of benefit and risk of aspirin treatment strategies for the primary prevention of cardiovascular diseases recommended by different guidelines in the Chinese Electronic Health Records Research in Yinzhou (CHERRY) study.

methodsA decision-analytic Markov model was used to simulate and compare different strategies of aspirin treatment, including: Strategy ①: Aspirin treatment for Chinese adults aged 40-69 years with a high 10-year cardiovascular risk, recommended by the 2020

resultsA total of 212 153 Chinese adults, were included in this study. The number of people who were recommended for aspirin treatment Strategies ①-③ was 34 235, 2 813, and 25 111, respectively. The Strategy ③ could gain the most QALY of 403 [95% uncertainty interval (

conclusionThe aspirin treatment strategies recommended by the updated guidelines on the primary prevention of cardiovascular diseases showed a net benefit for high-risk Chinese adults from developed areas. However, to balance effectiveness and safety, aspirin is suggested to be used for primary prevention of cardiovascular diseases with consideration for blood pressure control, resulting in better intervention efficiency.

Indexed as

Cardiovascular DiseasesMyocardial InfarctionAdultAgedAspirinGastrointestinal HemorrhageHumansMiddle AgedPrimary PreventionAspirinAspirinCardiovascular diseasesMarkov modelPrimary prevention

Identifiers

PMID37291924
PMCPMC10258046
OpenAlexW4379967273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.